Skip to content
Study details
Enrolling now

Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV

University of Maryland, Baltimore
NCT IDNCT06691243ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

40

Study length

about 1.6 years

Ages

18–65

Locations

2 sites in DC, MD

What this study is about

This trial is testing whether semaglutide is safe and well-tolerated in adults with cocaine use disorder, both with and without HIV. Participants will receive either semaglutide or a placebo for 601 days.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Placebo
  • 2.Take Semaglutide

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

semaglutide (GLP-1 agonist; stimulates insulin release)

Drug routes

oral (Oral Tablet)

Endpoints

Primary: Tolerability of semaglutide in patients with cocaine use disorder (CUD) with and without HIV

Body systems

Immune, Infectious